SMILES string
N1([C@@H]([C@H]([C@@H]([C@H](C1)O)O)O)CO)CCO
InChI key
IBAQFPQHRJAVAV-ULAWRXDQSA-N
InChI
1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1
biological source
synthetic (organic)
assay
≥98% (HPLC)
form
powder
mp
142-147 °C
solubility
water: 5 mg/mL, clear, colorless to faintly yellow
storage temp.
room temp
Quality Level
General description
Miglitol is an alpha-glucosidase inhibitor used as a glucose-lowering drug in diabetes research.
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Kazuki Mochizuki et al.
Bioscience, biotechnology, and biochemistry, 74(12), 2470-2474 (2010-12-15)
β(2) integrins (CD11s/CD18) promote the attachment of leukocytes to vascular endothelial cells. We performed in this study sucrose loading to rats with moderate postprandial hyperglycemia with/without once-daily dosing of the α-glucosidase inhibitor, miglitol, for 4 days under 4-h fasting conditions.
Kazuki Mochizuki et al.
Metabolism: clinical and experimental, 60(11), 1560-1565 (2011-05-10)
Otsuka Long-Evans Tokushima Fatty (OLETF) rats, an animal model of type 2 diabetes mellitus, exhibit chronic and slowly progressive hyperglycemia with obesity. In this study, we examined whether dietary supplementation with the α-glucosidase inhibitor miglitol from the preonset stage improves
Sheng-Hwu Hsieh et al.
Acta diabetologica, 48(1), 71-77 (2010-10-22)
The objective of this study is to examine the efficacy and tolerability of miglitol with respect to improving glycemic control in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylurea treatment. This was a randomized, double-blinded
Kenichi Matsuura et al.
Diabetes technology & therapeutics, 14(5), 423-429 (2012-02-10)
We compared the effects of miglitol as an add-on to bolus insulin and dose-intensified bolus insulin on postprandial glycemic excursions by continuous glucose monitoring (CGM). The glucose levels of 21 type 2 diabetes patients admitted for glycemic control were monitored
Kyra Jones et al.
Bioorganic & medicinal chemistry, 19(13), 3929-3934 (2011-06-15)
Inhibition of intestinal α-glucosidases and pancreatic α-amylases is an approach to controlling blood glucose and serum insulin levels in individuals with Type II diabetes. The two human intestinal glucosidases are maltase-glucoamylase and sucrase-isomaltase. Each incorporates two family 31 glycoside hydrolases
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持